Clinical trials · New York
Glioblastoma clinical trials in New York
We’re tracking 34 recruiting glioblastoma studies with a site in New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06991101RecruitingPhase 2
Ruxolitinib with radiation and chemo for new glioblastoma
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
New York, New YorkAges 18 years+ - NCT07089641RecruitingPhase 1
Testing a new pill for EGFR-mutated glioblastoma
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
New York, New YorkAges 18 years+ - NCT05879367RecruitingPhase 1
Eflornithine plus temozolomide for newly diagnosed brain cancer
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
New York, New YorkAges 18 years+ - NCT05271240RecruitingPhase 3
Targeted brain-artery drug added to standard treatment for new GBM
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
New York, New YorkAges 18 years+ - NCT05954858Recruiting
Surgical flap to help treat glioblastoma by bypassing the blood-brain barrier
This trial tests a surgical technique that places a tissue flap near a glioblastoma surgery site to help medicines reach the brain more effectively. You might be considered if you are planning major brain tumor surgery and meet specific health, imaging, and lab requirements.
New York, New YorkAges 18 years+ - NCT05979064Recruiting
Belly fat graft for recurrent brain tumor
This study tests if a piece of your own belly fat (omentum) placed in the brain during tumor surgery can help fight recurrent glioblastoma. It is for people who are already scheduled for surgery to remove their brain tumor.
New York, New YorkAges 18 years+ - NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Lake Success, New YorkAges 18 years+ - NCT03213002RecruitingPhase 1/Phase 2
CAPTEM pills after brain radiation for newly diagnosed glioblastoma
This trial studies whether taking two chemotherapy pills (capecitabine and temozolomide) after the initial 6-week radiation-and-chemo phase can help people with newly diagnosed glioblastoma. It aims to test safety and early effectiveness right before the usual maintenance temozolomide phase.
New York, New YorkAges 18–74 - NCT05303467RecruitingPhase 1
Safety study of a glioblastoma device for recurring tumors
This early study tests whether a device called TheraSphere is safe when delivered into the brain to treat recurrent glioblastoma. It may help patients by trying a targeted treatment approach, while doctors carefully monitor side effects and safety.
New York, New YorkAges 18 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
New York, New YorkAges 18 years+ - NCT02977780RecruitingPhase 2
Targeted treatment plan for specific glioblastoma tumor markers
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
New York, New YorkAges 18 years+ - NCT06816927RecruitingPhase 2
Immunotherapy trial for glioblastoma with nivolumab and relatlimab
This trial tests whether two immunotherapy drugs, nivolumab and relatlimab, can help treat glioblastoma (GBM), a type of brain tumor. It is for people newly diagnosed or who haven't had radiation or chemotherapy yet and are scheduled for surgery.
New York, New YorkAges 18 years+ - NCT05902169RecruitingPhase 3
Ultrasound with carboplatin for recurrent glioblastoma
This trial tests a device that opens the blood-brain barrier using ultrasound, allowing chemotherapy to reach the brain tumor better. It compares this approach to standard chemotherapy for people whose glioblastoma has returned.
New York, New YorkAges 18 years+ - NCT06556563RecruitingPhase 3
Optune with chemo and immunotherapy for new glioblastoma
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
Lake Success, New YorkAges 18 years+ - NCT07225621RecruitingPhase 2
Light and sound therapy for newly diagnosed glioblastoma
This trial tests a new approach that uses a light-sensitive drug and low-intensity ultrasound to make standard chemotherapy more effective for glioblastoma. If you have completed initial treatment with radiation and temozolomide without the tumor growing, you may be eligible.
Albany, New YorkAges 18–80 - NCT03970447RecruitingPhase 2/Phase 3
Testing several treatment options for new or returning glioblastoma
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
New York, New YorkAges 18 years+ - NCT05423210RecruitingEarly Phase 1
Atezolizumab with pre-surgery brain radiation for glioblastoma
This early-phase study tests atezolizumab (an immune therapy) together with radiation before brain surgery for glioblastoma. It aims to make the treatment safer and more effective before the tumor is removed.
Stony Brook, New YorkAges 18 years+ - NCT05432804RecruitingPhase 1/Phase 2
Selinexor added to temozolomide for recurring brain glioblastoma
This trial studies whether adding selinexor to the standard chemotherapy temozolomide (with radiation) can better treat glioblastoma that has come back after prior treatment. If you meet specific tumor, health, and lab requirements, the goal is to slow tumor growth or improve symptoms.
Buffalo, New YorkAges 18 years+ - NCT05463848RecruitingPhase 2
Surgery plus pembrolizumab with olaparib and temozolomide for glioblastoma
This trial tests a combination treatment after surgery for people with glioblastoma that has come back once or twice. It aims to improve control of the tumor by adding immune therapy and targeted DNA-damage treatment along with chemotherapy.
New York, New YorkAges 18 years+ - NCT06058988RecruitingPhase 2
T-DXd for people with brain cancer
This trial tests a drug called Trastuzumab Deruxtecan (T-DXd) for people with brain tumors that are either glioblastoma or have spread from other cancers. Doctors will see if T-DXd can shrink tumors or slow their growth, and they will collect tumor tissue during surgery or biopsy to study how the drug works.
New York, New YorkAges 18 years+ - NCT06504381RecruitingPhase 1/Phase 2
DB107 and radiation therapy for high-grade glioma
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
Lake Success, New YorkAges 18 years+ - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Mineola, New YorkAges 18 years+ - NCT06910306Recruiting
DaRT alpha radiation for recurrent glioblastoma
This trial tests a device called DaRT that delivers alpha radiation directly to a recurrent glioblastoma tumor. It may help patients who cannot have surgery and have a single, small tumor regrowth.
New York, New YorkAges 18–85 - NCT06934889RecruitingPhase 1
Study of ABBV-637 or ABBV-155 with ERAS-801 for recurrent glioblastoma
This trial tests two new drugs (ABBV-637 or ABBV-155) combined with ERAS-801 for people with recurrent glioblastoma (a type of brain cancer). It may help if your tumor has a specific genetic change (EGFR amplification) and you are having surgery to remove part of the tumor.
Commack, New YorkAges 18 years+
Glioblastoma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting glioblastoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 9 studies
- Columbia University Irving Medical Center · 8 studies
- Lenox Hill Hospital · 6 studies
- NYU Langone Health · 5 studies
- Northwell Health · 3 studies
- Montefiore Medical Center · 2 studies
- NYU Langone Health Perlmutter Cancer Center · 2 studies
- Albany Medical Center
What taking part in a glioblastoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Glioblastoma trials in other states
Common questions
- Are there glioblastoma clinical trials in New York?
- Yes. We're currently tracking 34 recruiting glioblastoma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a glioblastoma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a glioblastoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New glioblastoma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.